Cascinu S, Fedeli A, Fedeli S L, Catalano G
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy.
Ann Oncol. 1992 Jun;3(6):489-91. doi: 10.1093/oxfordjournals.annonc.a058244.
Because of the different sites and mechanisms of biochemical interaction among 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN), we hypothesized that the concomitant use of IFN could increase the activity of the 5-FU/LV combination in colorectal cancer patients. Forty-five patients were included in the study and all were evaluable for response and toxicity. They were treated with 5-FU 370 mg/sqm i.v. d 2-6; LV 200 mg/sqm i.v. d 2-6; IFN alpha 2b 3 million U im d 1-7 every 21 days. Six patients achieved complete responses, 17 partial responses, 14 had stable disease and 8 progressed on therapy for an overall response rate of 51%. Median survival has not been reached. At a median follow-up of 14 months 33 of 45 patients remain alive. Nine patients experienced toxicity grade 3 (6 diarrhea and 3 stomatitis). Our results seem to suggest that IFN could increase 5-FU/LV activity and that this combination is well tolerated.
由于5-氟尿嘧啶（5-FU）、亚叶酸钙（LV）和干扰素（IFN）之间生化相互作用的位点和机制不同，我们推测，同时使用IFN可能会增强5-FU/LV联合用药对结直肠癌患者的疗效。本研究纳入了45例患者，所有患者均对疗效和毒性可进行评估。他们接受的治疗方案为：5-FU 370 mg/m²静脉注射，第2 - 6天；LV 200 mg/m²静脉注射，第2 - 6天；IFNα2b 300万U皮下注射，第1 - 7天，每21天重复一次。6例患者达到完全缓解，17例部分缓解，14例病情稳定，8例在治疗过程中病情进展，总缓解率为51%。中位生存期尚未达到。在中位随访14个月时，45例患者中有33例仍存活。9例患者出现3级毒性反应（6例腹泻和3例口腔炎）。我们的结果似乎表明，IFN可以增强5-FU/LV的疗效，且这种联合用药耐受性良好。
